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Background: Glutamate, the main excitatory neurotransmitter, is involved in learning and memory processes but at
higher concentration results excitotoxic causing degeneration and neuronal death. Adenosine is a nucleoside that
exhibit neuroprotective effects by modulating of glutamate release. Hypoxic and related oxidative conditions, in
which adenosine and metabotropic glutamate receptors are involved, have been demonstrated to contribute to
neurodegenerative processes occurring in certain human pathologies.
Results: Human neuroblastoma cells (SH-SY5Y) were used to evaluate the long time (24, 48 and 72 hours) effects of
a [60]fullerene hydrosoluble derivative (t3ss) as potential inhibitor of hypoxic insult. Low oxygen concentration
(5% O2) caused cell death, which was avoided by t3ss exposure in a concentration dependent manner. In addition,
gene expression analysis by real time PCR of adenosine A1, A2A and A2B and metabotropic glutamate 1 and 5
receptors revealed that t3ss significantly increased A1 and mGlu1 expression in hypoxic conditions. Moreover, t3ss
prevented the hypoxia-induced increase in A2A mRNA expression.
Conclusions: As t3ss causes overexpression of adenosine A1 and metabotropic glutamate receptors which have
been shown to be neuroprotective, our results point to a radical scavenger protective effect of t3ss through the
enhancement of these neuroprotective receptors expression. Therefore, the utility of these nanoparticles as
therapeutic target to avoid degeneration and cell death of neurodegenerative diseases is suggested.
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Low oxygen availability in neuronal cells is the main
cause of cognitive and physical deficiencies in patients
who suffered ischemic toxicity in brain. Even though
various factors are involved during the partial decrease
of oxygen concentration in cells, the activation of spe-
cific factors named HIFs (hypoxia inducible-factors),
which induce the transcription of specific genes involved* Correspondence: jose.albasanz@uclm.es
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unless otherwise stated.in several transduction pathways, mainly happen at low
concentrations of oxygen in cells [1]. The consequent
oxidative stress has been related to cell death processes,
generally apoptotic, upon the formation of reactive oxy-
gen species (ROS) and subsequently oxidative modifica-
tions of lipid, DNA, cell membrane proteins and other
target molecules. The oxidative stress has been further-
more related to the development of some neurodegener-
ative diseases as Alzheimer’s and Parkinson’s [2]. The
oxidative damage by free radicals is known to be origi-
nated in mitochondrial respiratory chain by complex I and
III as source of superoxide anion (O2
−) [3]. However, these
organelles have protective antioxidant enzymes that convert
reactive species into no toxic ones [4]. Some of these en-
zymes belong to the family of superoxide dismutase (SOD),d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing H2O2 into water, and other enzymes like glutathione re-
ductase, whose expression is induced by ROS. Nevertheless
some enzymes may change their function from antioxidant
to oxidant, mainly due to the increase of iron and copper
linked to brain aging [2]. Thus a dramatic increase in ROS
has been related to cell death induced by oxidative stress
and to neurodegenerative diseases as Alzheimer’s [5].
Apoptotic cell death is mainly mediated by an increase in
mitochondrial permeability to calcium which promotes
cytochrome c release [6]. In that sense, it has been pro-
posed that the first step of Alzheimer’s disease is the oxida-
tive damage originated by ROS [7].
Adenosine and metabotropic glutamate receptors
(mGluR) have been largely studied for their implication
in hypoxic injury. It has been repeatedly shown that ad-
enosine can protect tissues against the negative conse-
quences of hypoxia or ischemia [8,9], mainly by acting
on the A1AR. Hence, survival after a hypoxic challenge
may be reduced if A1ARs are absent or blocked [10]. Be-
cause the A2BAR promoter contains a functional binding
site for hypoxia-inducible factor, the onset of hypoxia
strongly induces its expression [11]. Moreover, a tissue
protective role of A2BAR signaling during hypoxic condi-
tions has been reported [12]. On the other hand, it has
been described the role of mGluRs during hypoxic con-
ditions. The protective effect of mGluRs of group I and
the involvement of protein kinase C during hypoxic con-
ditions have been reported [13]. In addition, Opitz and
co-workers described in rat hippocampal slices dissimilar
responses to hypoxic conditions depending on different
group of mGluRs involved. Thus, the activation of group
II was found to decrease cell recovery from hypoxia.
However, a beneficial role of pre-activation of group I, as
well as their detrimental role if activated during hypoxic
conditions, was reported [14].
Fullerene derivatives are effective redox-active com-
pounds towards ROS such as superoxide anion radical
(O2
−), hydroperoxide (ROOH), and hydroxyl radical
(•OH) produced during oxidative stress and responsible
for different type of cell damages [15]. These properties
are peculiar of fullerenes because of their general low en-
ergy of LUMO (Lowest Unoccupied Molecular Orbital)
towards a high HOMO (Highest Occupied Molecular Or-
bital) level, conferring them radical quenching properties.
For example, a polyhydroxylated C60 (fullerenol) was re-
ported to have quenching activity for O2
− [16]. Further-
more, it has been demonstrated that fullerenol presents a
decreased ROS quenching activity with respect to the par-
ent C60 since conjugated double bonds are widely broken.
Thus, experiments with C60-dimalonic acid, having prop-
erties rather similar to C60, demonstrated its major efficacy
in quenching radical species. This activity seems to be re-
lated to anti-aging and neuroprotective effect of fullerenederivatives [17,18]. Therefore, [60]fullerene may be con-
sider as the ideal candidate for protective properties in liv-
ing systems subjected to oxidative stress even though the
functionalization of [60]fullerene, used to increase its solu-
bility in aqueous systems for better interfacing with bio-
logic systems, is often accomplished with a partial loss of
its antioxidant activity. Nevertheless, it was demonstrated
that the bis-functionalization of [60]fullerene by means of
azomethine ylide 1,3 dipolar cycloaddition leading to bis-
pyrrolidine derivatives, confers a certain electronic stability
to the fullerene carbon cage without depriving its quench-
ing properties towards radical species [19]. In that sense, a
series of highly hydrosoluble [60]fullerene bis-adducts
were synthesized and encouraging results on assays in bio-
logical substrates have been obtained [20]. The aim of the
present work was to study the possible protective effect of
the trans-3 isomer of [60]fullerene (t3ss) in SH-SY5Y cells
subjected to hypoxic conditions and the involvement of




The hydrosoluble [60]fullerene bis-adduct trans-3 (t3ss)
was synthesized as described in Figure 1. All reagents and
solvents employed were from Sigma Aldrich (Germany). For
an exhaustive reference of the product synthesis see [20].
Cell culture
Human neuroblastoma SH-SY5Y cells (acquired from
American Type Cell Collection) were grown in DMEM
(Dulbecco’s Modified Eagle’s Medium) supplemented with
10% fetal bovine serum, and 1% of mixture antibiotic-
antimycotic (Gibco, USA), humidified atmosphere with
5% CO2 at 37°C. SH-SY5Y cells were subcultured (pas-
sages 3–12) on 10 ml Petri dish (Nunc, Denmark). At con-
fluence, they were detached by Trypsin (Tryple Express,
Gibco, USA), centrifuged and the cells re-suspended in
complete growth medium and plated onto 24- or 96-well
dishes (Nunc, Denmark) to have a final density per well of
2 × 105 and 3 × 104 cells, respectively.
MTT reduction assay
Cell viability was determined using an in vitro toxicology
assay kit based on the reduction of 3-[4,5-dimetylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) purchased
from Sigma (Madrid, Spain), according to Mosmann [21].
Briefly, SH-SY5Y cells were seeded at 3 × 104 cells per well
in 96-well dishes and exposed to hypoxic conditions
(95% N2; 5% O2) for desired period (6, 24, 48 and 72 h)
and treated with different t3ss concentrations (25–
150 μM). At the end of hypoxic insults or fullerene deriva-
tive treatment, cells were incubated in culture medium
with MTT solution (5 mg/mL) at 37°C for 3 h. After
Figure 1 Synthetic scheme for trans-3 isomer [60]fullerene bis-adduct derivative (t3ss). R1 = CH2CH2OCH2CH2OCH2CH2NHBoc. Reagent and
conditions: (i) molar ratio A:B:C 1:2:5, toluene, 2 h at reflux, isolation of trans-3 isomer among the reaction mixture; (ii) CH3I, CH2Cl2, 24 h at 80°C;
(iii) HCl (g), CH3OH, 20 min at 0°C. For more details and procedures see [20].
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100 plus 0.1 N HCl in anhydrous isopropanol) was added
to the wells to dissolve formazan crystals. The plates were
thoroughly shaken and the absorbance of each well was
measured at 570 nm.
Total RNA isolation and preparation of cDNA
Total RNA was extracted from cells using an ABI 6100
Nucleic Acid PrepStation and chemicals according to the
manufacturer’s protocol (Applied Biosystems, Foster City,
CA). Ratio of A260/A280 (RNA purity) was in the range
1.9-2.1. RNA concentrations were determined from the
A260. Total RNA was isolated and stored at −80°C. One
microgram of total RNA was reverse transcribed using
Applied Biosystems’ High-Capacity cDNA Archive Kit ac-
cording to manufacturer’s protocol.
Quantitative real time RT-PCR analysis
To assess relative gene expression in SH-SY5Y neuro-
blastoma cells, quantitative real time RT-PCR analysis
[22] was performed with an Applied Biosystems Prism
7500 Fast Sequence Detection System, using TaqMan
universal PCR master mix according to the manufac-
turer’s specifications (Applied Biosystems, Foster City,
CA). The TaqMan probes and primers for A1 (assay ID:
Hs00181231), A2A (assay ID: Hs00386497), A2B (assay
ID: Hs00169123), mGlu1 (assay ID: Hs00168250),
mGlu5 (assay ID: Hs00168275), and β-actin (assay ID:
Hs99999903) were assay-on-demand gene expressionproducts (Applied Biosystems). TaqMan® Gene Expres-
sion Assays all have an efficiency of 1.0, which means a
doubling of PCR product in every cycle is guaranteed.
The TaqMan primer and probe sequences are packaged to-
gether in a 20× solution. The sequences are proprietary, so
they are not available. The gene-specific probes were la-
beled using reporter dye FAM. A non-fluorescent quencher
and the minor groove binder were linked at the 3’ end of
probe as quenchers. The thermal cycler conditions were as
follows: hold for 20 s at 95°C, followed by two step PCR for
40 cycles of 95°C for 3 s followed by 60°C for 30 s. Levels of
RNA expression were determined using the 7500 Fast Sys-
tem SDS software version 1.3.1 (Applied Biosystems)
according to the 2−ΔΔCt method. Briefly, expression re-
sults of a gene were normalized to endogenous control
β-actin relative to a calibrator (normoxia sample), con-
sisting of the mean expression level of the receptor
gene as follows: 2−ΔΔCt = 2 − ((Ct receptor gene − Ct actin)
sample − (Ct receptor gene − Ct actin) calibrator). β-actin is an
appropriated endogenous control as its expression did
not change after t3ss exposure [23,24]. The results from
4–5 independent repeat assays, performed in different
plates each using different cDNA’s from the cultures an-
alyzed, were averaged to produce a single mean value
for each mRNA.
Statistical and data analysis
Data statistical analysis was performed using Student t-
test and one-way ANOVA test and Dunnett post test
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San Diego, CA, USA). Differences between mean values
were considered statistically significant at p < 0.05.
Results and discussion
MTT assays showed a significant cell death after 6 and
24 h of hypoxic insult (5% O2). Interestingly, cell viability
was strongly recovered when t3ss was present during hyp-
oxia being this effect concentration dependent (Figure 2).
This protective effect of t3ss was detected and very similar
at both 6 and 24 hours hypoxic insult.
Next step was to test the possible role of t3ss on gene
expression modulation of receptors involved in neurode-
generative processes and diseases, such as adenosine
(AR) and metabotropic glutamate receptors (mGluR)
[25-27]. Even though the treatment of SH-SY5Y cells
with 75 μM t3ss derivative exhibited similar significant
protective effect in both the 6 and 24 h period of hyp-
oxia, as observed from MTT assay, in the shorter period
of treatment, we did not observe any change in gene ex-
pression from qPCR (data not shown). Therefore, we
assessed the effect of t3ss (75 μM) on gene expression
for 24 h and longer periods (48 and 72 h) of exposure to
hypoxic insult.
Results from qPCR assays revealed a constant gene ex-
pression of all the receptors analyzed in the present study
during the considered periods of time (24, 48 and 72 h) in
normoxia (Figure 3). Only A2A mRNA expression wasFigure 2 MTT reduction viability assay on SH-SY5Y cells after hypoxic
t3ss derivative. SH-SY5Y cells were subjected to 6 and 24 h of hypoxic co
[60]fullerene hydrosoluble t3ss derivative (t3ss) (25–150 μM). The obtained
following MTT reduction assay protocol as described in Methods. The dotte
normal oxygen conditions (21% O2). *p < 0.05, **p < 0.01, ***p < 0.001 signi
according to Student t-test.significantly enhanced at 24 h and longer time in hypoxia,
pointing out to a possible role of A2A in the viability loss
detected at 24 h. A slight not significant increase of A2B ex-
pression was also detected, while the others genes analyzed
were not modified by hypoxia at any time assayed.
Interestingly, although t3ss did not change the expres-
sion of the analyzed genes when applied in normoxia, it
significantly reduced the hypoxia-induced increase in
A2A expression. Moreover, t3ss also increased A1 and
mGlu1 expression after 24 h in hypoxia, being this effect
maintained at 48 and 72 h. However, t3ss did not modify
A2B and mGlu5 gene expression during hypoxia.
These results show that the protective effect of [60]ful-
lerene derivative against hypoxia, with increased effective-
ness at higher concentrations, could be attributed, at least
in part, to its modulatory effect on target receptor genes.
The neuroprotection induced by adenosine operates two
well-known synaptic actions of A1ARs that also occur
under normoxic conditions and are of particular relevance
in the case of hypoxia: a decrease of neurotransmitter re-
lease via inhibition of presynaptic calcium entry through
the blocking of calcium channels [28], and postsynaptically
inhibiting calcium entry via inhibition of NMDA (N-me-
thyl-D-aspartate) receptors [29]. In line with this, the
observed increase in A1ARs gene expression by t3ss de-
rivative, as it has been previously reported in SK-N-MC
cells [23], could be related to the described protective role
exerted by these receptors during hypoxic conditions [30].conditions (5% O2, 95% N2) in the absence or the presence of
ndition in the presence or absence of different concentrations of
values are the average of three independent experiments, collected
d line indicates the 100% of cells survival intended as cells growing in
ficantly different from cells survival in the absence of t3ss derivative
Figure 3 Gene expression evaluated by quantitative real time-PCR in SH-SY5Y cells exposed to hypoxic and normoxic conditions.
SH-SY5Y cells were subjected normoxia and hypoxia (5% O2) during 24, 48 and 72 hours, in the absence and in the presence of 75 μM t3ss
derivative. The corresponding RNA was analyzed by quantitative real time PCR, as described in Methods, using the following gene targets: adenosine
A1, A2A, A2B receptors, mGlu1 and mGlu5 receptors. Data are mean ± SEM of four to five independent experiments. ## p < 0.01 significantly different
from the value at the corresponding time in normoxia; *p < 0.05, **p < 0.01 and ***p < 0.001, significantly different from the value at the corresponding
time in hypoxia, according to ANOVA test and Dunnett post test.
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A1 and A2A receptors during hypoxic conditions in rat
C6 glioma cells, where hypoxia (5% O2) caused a signifi-
cant decrease in A1 receptors while A2A receptors were
significantly increased through a mechanism in which
endogenous adenosine and tonic A1 receptor activation
is involved [31]. On the other hand, it has been demon-
strated that during oxidative stress and related toxicity,
the use of antagonists of adenosine A2A receptors may
be considered a valid therapeutic approach [32]. More-
over, it has been reported that A2AARs modulate glu-
tamate uptake in cultured astrocytes and gliosomes [33]
and stimulate glutamate release, thus promoting in-
creased glutamate levels which could be excitotoxic
mainly through NMDA receptors overactivation. How-
ever, protective effects related to survival of neurons
have been attributed to the group I of metabotropic glu-
tamate receptors, mainly mGlu1 [34].
Fullerene derivatives may act on NMDA receptors and
on the variation of Ca2+ homeostasis and inhibit the excito-
toxic death, as it has been reported in cultured cortical
neurons exposed to NMDA agonist [17]. The Ca2+ homeo-
stasis has been reported to be also modulated by mGlu1
receptors as they regulate voltage dependent calcium chan-
nels [35]. Thus, the effect of t3ss derivative on the modula-
tion of mGlu1 gene expression could be hypothetically
related to the one reported for mGlu1 antagonists, which
reduce the damage in post ischemic conditions [36]. Theherein proposed possible modulatory effect of t3ss on
NMDA receptors, and consequently on Ca2+ homeostasis
could be related to the modulation of the expression of
metabotropic glutamate receptor belonging to group I [37].
Both mechanisms of action of t3ss could thus lead to the
protective effect observed during MTT viability assay, act-
ing both synergically or independently one from the other.
In summary, results presented herein show for the first
time that the modulation of adenosine and metabotropic
glutamate receptors exhibited by a [60]fullerene deriva-
tive which could be, at least in part, responsible for its
neuroprotective effect against hypoxic insults. Given that
hypoxia and subsequent adenosine generation is likely
an acute response to numerous injuries, including neu-
rodegenerative diseases as Alzheimer’s, the modulation
of adenosine and metabotropic glutamate receptors by
t3ss during hypoxia could open new lines of research in
the field of therapeutics.
Conclusions
In the present paper SH-SY5Y cells were used as a model
to hypoxic injury which caused cell death. Hypoxia has
been related to neurodegeneration characteristic of many
neurodegenerative diseases. Adenosine and metabotropic
glutamate receptors have been shown to be impaired in
Alzheimer’s disease and other neurodegenerative diseases.
Results from this work show that a hydrosoluble fullerene
derivative (t3ss) is able to avoid the cell death during
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adenosine A1 and metabotropic glutamate receptors ex-
pression during hypoxia. Therefore, our results suggest
fullerenes as neuroprotective molecules and open new
therapeutic perspectives to be considered to avoid de-
generation and neuronal death which is related to neu-
rodegenerative diseases. However, additional studies
will be necessary in order to confirm this hypothesis.
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